Dragović, Gordana (23396934400)Gordana (23396934400)DragovićSalemović, Dubravka (7801387340)Dubravka (7801387340)SalemovićRanin, Jovan (6603091043)Jovan (6603091043)RaninNikolić, Jelena (57207516168)Jelena (57207516168)NikolićKušić, Jovana (56014110700)Jovana (56014110700)KušićJevtović, Djordje (55410443900)Djordje (55410443900)Jevtović2025-06-122025-06-122014https://doi.org/10.1080/03630242.2013.850465https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894260844&doi=10.1080%2f03630242.2013.850465&partnerID=40&md5=767d7b28fd87937f7f01b767eee5a7e5https://remedy.med.bg.ac.rs/handle/123456789/8893We performed a study to identify factors related to favorable response to highly active-antiretroviral therapy (HAART) in HIV-infected women. A retrospective study was performed on 216 women who had initiated HAART from January 1, 1998 to December 31, 2012, at the HIV/AIDS Center, Belgrade, Serbia. Participants were followed-up for 8.2 ± 3.4 years. The mean age was 37 ± 9.7 years. During follow-up, it was found that 26 patients had died. Clinical AIDS at initiation of HAART was observed in 43.9% patients, while 64.8% had a CD4+ T-cell count below 200 cells/μL. Multivariate analyses revealed that the single factor independently related to a favorable response to HAART was good compliance (odds [OR] ratio for survival = 2.9, 95% confidence intervals [CI] = 1.0-8.6, p = 0.03), while a baseline CD4+ T-cell count below 100 cells/μL, hepatitis C virus coinfection, and aged 40 years and older were all associated with an unfavorable response to HAART (OR = 0.28, 95% CI = 0.15-0.52, p < 0.001; OR = 0.49, 95% CI = 0.22-0.8, p = 0.008; OR = 0.41, 95% CI = 0.21-0.79, p = 0.008, respectively). The estimated 14-year-survival was 100% in patients with sustained viral suppression, regardless of the CD4+ counts achieved (p = 0.6, log-rank). If women with advanced HIV-related immunodeficiency reach and maintain optimal viral suppression during HAART, regardless of the level of immune recovery, and if they continue to maintain this suppression for up to a mean 8 years of treatment, their prognosis may be fairly good, even in resource-limited settings. © 2014 Copyright Taylor and Francis Group, LLC.highly active-antiretroviral therapy (HAART)HIVsurvivalwomen